Skip to search formSkip to main contentSkip to account menu

Femara

Known as: Femara®, Fémara, Novartis Brand of Letrozole 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (5)

Antineoplastic AgentsEnzyme InhibitorsNitrilesTriazoles
CGS 20267letrozole 2.5 MG Oral Tablet [Femara]letrozole/tamoxifen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Aromatase Inhibitors Such as Letrozole (Femara) vs. Clomiphene (Clomid) for Subfertile Women with PCOS.
When treated with letrozole, subfertile women with PCOS who are trying to conceive have increased chances of pregnancy (number… 
2017
2017
Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
Background: In early ER+ breast cancer, neo-adjuvant (NA) endocrine therapy (ET) may identify a subset of patients with endocrine… 
2016
2016
Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and…
Background The FACE trial was designed to evaluate the efficacy and safety of adjuvant letrozole (LET) versus anastrozole (ANA… 
Review
2011
Review
2011
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
On April 30, 2010, the U.S. Food and Drug Administration converted letrozole (Femara®; Novartis Pharmaceuticals Corporation, East… 
Review
2007
Review
2007
Femara® and the future: tailoring treatment and combination therapies with Femara
Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular… 
2007
2007
Tamoxifène versus inhibiteurs de l'aromatase : quels bénéfices pour quelle tolérance ?
FEMARA 2,5 mg comprimé pelliculé (létrozole). FORME,PRÉSENTATION ET COMPOSITION. FORME,PRÉSENTATION ET COMPOSITION :Comprim… 
2006
2006
Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting.
10532 Background: Aromatase inhibitors of the third generation like letrozole, anastrozole and exemestane are known to suppress… 
2005
2005
Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer
AbstractObjective: To compare the response and adverse reactions of aminoglutethimide with that of femara, an oral aromatase… 
2004
2004
Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer
6044 Background: The MA17 study was a randomized double-blind placebo-controlled trial of 5 years of letrozole (Femara®) 2.5 mg/d… 
2001
2001
Femara approved as first-line breast cancer therapy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)